Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8

NCT00218036 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2018-11-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine two medications, modafinil and citalopram, in the treatment of cocaine dependent individuals who are maintained on methadone.

Conditions

  • Cocaine Abuse
  • Opiate Dependence

Interventions

DRUG

Modafinil 200mg

10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.

DRUG

Modafinil 400mg

10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.

DRUG

Citalopram 20mg

10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.

DRUG

Citalopram 40mg

10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.

DRUG

Placebo

Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH
  • University of Texas

    collaborator OTHER
  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Joy M Schmitz, PhD · University of Texas

  • F. Gerard Moeller, M.D. · University of Texas Medical School at Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00218036 on ClinicalTrials.gov